Patent · US Active

Anticancer agents

US11730736B2 · kind B2 · utility

1Cited by
4References
15Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 5, 2018
Grant dateAug 22, 2023
Priority date—
Expiry dateNov 5, 2038

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K45/06
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed herein are therapeutic methods of administering compounds that modulate the C—C chemokine receptor type 4 (CCR4) for the treatment of Epstein Bar virus (EBV) positive cancers and malignancies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.